0.2mg/kg ketamine with psychotherapy for Post-Traumatic Stress Disorder

Yale University School of Medicine, New Haven, CT
Post-Traumatic Stress DisorderKetamine - Drug
Eligibility
21 - 70
All Sexes

Study Summary

This trial will test if ketamine + intensive psychotherapy can help relieve PTSD faster than midazolam + psychotherapy. It may produce significant changes in a week, vs months.

Eligible Conditions
  • Post Traumatic Stress Disorder

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: Baseline, 7 days, 30 days and 90 days

Day 30
Measure the changes in psychophysiological distress to trauma reminders as a result of the proposed intervention
Day 90
To determine if ketamine + exposure therapy results in more profound changes in task-based connectivity in region of interest than midazolam + exposure therapy (Phase 2; combined R61/R33 data)
Day 90
Change from baseline to 90 days post treatment in Beck Depression Inventory (BDI-II)
To determine if ketamine + exposure therapy results in clinical improvement in PTSD symptoms which are significantly greater than midazolam + exposure therapy (Phase 2; combined R61/R33 data)
Changes from baseline to 30-day post-treatment in amygdala activation to the trauma memory
Amygdala activation to trauma memory (Phase 1; R61)

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

3 Treatment Groups

Midazolam with psychotherapy
1 of 3
0.2mg/kg ketamine with psychotherapy
1 of 3
0.5mg/kg ketamine with psychotherapy
1 of 3

Active Control

Experimental Treatment

162 Total Participants · 3 Treatment Groups

Primary Treatment: 0.2mg/kg ketamine with psychotherapy · No Placebo Group · Phase 2

0.2mg/kg ketamine with psychotherapy
Drug
Experimental Group · 1 Intervention: Ketamine · Intervention Types: Drug
0.5mg/kg ketamine with psychotherapy
Drug
Experimental Group · 1 Intervention: Ketamine · Intervention Types: Drug
Midazolam with psychotherapy
Drug
ActiveComparator Group · 1 Intervention: Midazolam · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
2011
Completed Phase 4
~1160

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 7 days, 30 days and 90 days

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,619 Previous Clinical Trials
1,983,095 Total Patients Enrolled
Yale UniversityLead Sponsor
1,728 Previous Clinical Trials
20,525,414 Total Patients Enrolled
Ilan Harpaz-Rotem, PhD ABPPPrincipal InvestigatorYale University

Eligibility Criteria

Age 21 - 70 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Does the trial accept participants who are past retirement age?

"As indicated in the inclusion criteria, only individuals between 21 and 70 may apply for this clinical trial. There are 44 studies dedicated to those under 18 while a seperate 328 trials cater to patients over 65 years old." - Anonymous Online Contributor

Unverified Answer

Is this research actively seeking new participants?

"The medical trial is actively recruiting, as seen on the clinicaltrials.gov website. It was first advertised to potential participants on June 1st 2023 and has since been updated on May 18th 2023." - Anonymous Online Contributor

Unverified Answer

How many patients are currently enrolled in this exploration of medical treatments?

"Affirmative. Clinicaltrials.gov hosts the official data which demonstrates that this medical trial is presently enrolling participants; it was initially posted on June 1st 2023 and most recently updated on May 18th 2023. The study seeks to include 162 patients at a single site." - Anonymous Online Contributor

Unverified Answer

Has the FDA sanctioned a combination of 0.2mg/kg ketamine and psychotherapy?

"According to our team at Power, the safety of 0.2mg/kg ketamine combined with psychotherapy was rated a 2 on a scale from 1-3 due to Phase 2 trial data which confirms its general security but lacks efficacy evidence." - Anonymous Online Contributor

Unverified Answer

Who are the potential participants for this research endeavor?

"This clinical trial seeks 162 individuals with post-traumatic stress disorder who range in age from 21 to 70. Primarily, the participants should be male or female and within this arbitrary age bracket due to prior research showing no adverse effects of ketamine on adults aged 18-20 being less than mature enough for such a protocol. Females may join if they are not expecting offspring and use medically accepted contraceptive methods (including oral contraceptives, injectable contraception, intrauterine devices etc.) or have gone through menopause for at least one year. Furthermore, applicants must possess severe PTSD as evidenced by CAPS-5 score of 25 or higher; furthermore" - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.